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Background. Human immunodeﬁciency virus (HIV) infection–induced indoleamine 2,3-dioxygenase-1 (IDO)
expression in activated monocytes and dendritic cells catabolizes tryptophan to kynurenine and other downstream
catabolites that inhibit T-cell proliferation and interleukin 17 (IL-17) production. The prognostic signiﬁcance of this
pathway in treated HIV disease is unknown.
Methods. We measured systemic IDO activity (calculated as the ratio of plasma levels of kynurenine to trypto-
phan; hereafter, the “KT ratio”) in HIV-infected Ugandans before and during antiretroviral therapy (ART)–mediated
viral suppression and its association with the rate of subsequent CD4+ T-cell count recovery and mortality.
Results. Among 435 participants, a higher pre-ART KT ratio was associated with a higher plasma virus load
(P < .001) and lipopolysaccharide level (P = .018), a lower CD4+ T-cell count (P < .001), and female sex (P = .047).
Through month 12 of ART-mediated viral suppression, the plasma KT ratio decreased by approximately 50%
(P < .001). After adjustment for pre-ART CD4+ T-cell count, virus load, age, and sex, a higher month 12 KT ratio
predicted a slower rate of subsequent CD4+ T-cell count recovery (P = .001). Thirty-nine participants died. After
adjustment for pre-ART CD4+ T-cell count, virus load, body mass index, sex, and age, a higher pre-ART and
month 6 KT ratio predicted increased mortality (P≤ .016).
Conclusions. The kynurenine pathway of tryptophan catabolism independently predicts poor CD4+ T-cell
count recovery and increased mortality among HIV-infected Ugandans initiating ART and may be an important
target for interventions.
Keywords. Tryptophan; kynurenine; indoleamine 2,3-dioxygenase-1; HIV; mortality; antiretroviral therapy; Uganda.
Immune activation has long been recognized as a key
feature of human immunodeﬁciency virus type 1
(HIV-1) pathogenesis, remains abnormally elevated de-
spite antiretroviral therapy (ART)–mediated viral sup-
pression, and predicts morbidity and mortality in this
setting [1]. Thus, developing interventions to reverse
immune activation during treated HIV disease has
emerged as a major priority for the modern HIV treat-
ment era. Nevertheless, the pathways that are optimal
targets for interventions have remained unclear.
One potentially attractive therapeutic target is indole-
amine 2,3-dioxygenase-1 (IDO) and the kynurenine
pathway of tryptophan catabolism. IDO is induced in
dendritic cells and monocytes by interferon γ (IFN-γ),
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IFN-α, lipopolysaccharide (LPS) and other inﬂammatory medi-
ators in HIV-infected individuals [2–4]. IDO catabolizes trypto-
phan to kynurenine and a variety of downstream catabolites
that are potentially neurotoxic and immunoregulatory. For ex-
ample, the downstream catabolite quinolinic acid may contrib-
ute to several neurodegenerative diseases, including AIDS
dementia complex [5–8]. The tryptophan catabolites kynurenine
and picolinic acid also inhibit T-cell proliferation [9, 10], which
may play an essential role in maternal tolerance of the fetal allo-
graft during pregnancy [11] and in the evasion of host immune
responses by several cancers [12]. Last, the tryptophan catabolite
3-hydroxyanthralinic acid (3-HAA) induces loss of T-helper type
17 (Th17) cells in HIV-infected individuals, potentially contrib-
uting to microbial translocation and immune activation [13–18].
Since microbial translocation may further induce IDO expres-
sion, a vicious cycle may result that perpetuates Th17 depletion,
microbial translocation, and immune activation, even after HIV
replication is controlled during ART [19]. The activity of this
pathway can be quantiﬁed in vivo by measuring the ratio of ky-
nurenine to tryptophan (hereafter, the “KT ratio”), in which a
high KT ratio reﬂects heightened activation of the IDO pathway
(and IDO-like enzymes) and greater catabolism of tryptophan to
its potentially harmful catabolites. While constitutive activity of
the hepatic enzyme tryptophan 2,3-dioxygenase and enrichment
for gut bacteria with IDO-like enzymesmay also contribute to the
high plasma KT ratios in HIV disease [13, 20], IDO is thought to
be the primary inducible systemic driver of the kynurenine path-
way of tryptophan catabolism.
Abnormally high plasma KT ratios have long been observed
in untreated HIV infection and cross-sectionally associated with
progressive HIV disease and AIDS dementia complex in the
pre-ART era [21–25]. A high KT ratio also predicts earlier mor-
tality in elderly HIV-uninfected individuals [26, 27]. The plas-
ma KT ratio declines during ART-mediated viral suppression
but fails to normalize [21, 22]. No study, however, has addressed
whether the plasma KT ratio predicts subsequent clinical events
in treated HIV disease.
To address this issue, we measured the plasma KT ratio
through the ﬁrst year of ART and assessed its relationship to sub-
sequentCD4+T-cell count recoveryandmortality inHIV-infected
individuals starting their ﬁrst ART regimen in the Uganda AIDS
Rural Treatment Outcomes (UARTO) cohort. We chose the
UARTO cohort for this initial study on the basis of its relatively
large number of deaths during early ART, its very low rates of
losses to follow-up, and the availability of T-cell activation data
(as a comparator immunologic predictor) [28].
METHODS
Participants
HIV-infected participants were sampled from UARTO, a co-
hort of HIV-infected adults initiating their ﬁrst ART regimen
at the Immune Suppression Clinic in Mbarara, Uganda. All par-
ticipants commence ART with 2 nucleoside reverse transcriptase
inhibitors and a nonnucleoside reverse transcriptase inhibitor.
Participants are seen before commencement of ART and then
every 3 months. At each visit, detailed interviews are conducted,
and a blood specimen is obtained between 8:00 AM and 9:30 AM
(before a meal) for CD4+ T-cell counts, plasma HIV RNA levels,
and biologic specimen archiving. The cohort also features an ac-
tive vital status ascertainment program for tracking participants
who are lost to follow-up. For the present analysis, all UARTO
participants who initiated ART before 2011 and had pre-ART
plasma specimens available were sampled.
Measurements
Plasma HIV RNA levels were assessed using the Amplicor HIV
Monitor 1.5 test (Roche, Branchburg, NJ; lowest level of detec-
tion, 400 copies/mL) or the Cobas Taqman HIV-1 test v1.0
(Roche; lowest level of detection, 48 copies/mL). CD4+ T-cell
counts were assessed in the Makerere University/Johns Hopkins
University laboratory in Kampala, Uganda. Self-reported dietary
protein intake was assessed in a consecutive subset of 361 partic-
ipants, using a dietary diversity scale, which assesses consump-
tion of food in 12 different groups in a reference 24-hour
period, as previously described [29]. Plasma tryptophan and ky-
nurenine levels were assessed on cryopreserved ACD-anticoagu-
lated plasma samples from pre-ART time points (all participants)
and at months 6 and 12 of ART among those with plasma HIV
RNA levels of <400 copies/mL. Liquid chromatography–tandem
mass spectrometry was used to assess kynurenine and tryptophan
levels as previously described [13, 30], and the KT ratio was ex-
pressed in nanomoles per micromoles. Lipopolysaccharide (LPS)
levels were also assessed on ACD-anticoagulated plasma with the
Limulus amebocyte assay by use of the heat and dilution method
for extracting LPS from plasma lipoproteins and subtracting the
background absorbance as described previously [31]. The fre-
quency of activated (CD38+HLA-DR+) CD4+ and CD8+ T cells
was assessed on fresh whole-blood specimens processed the same
day as described previously [28].
Statistical Methods
For cross-sectional comparisons, continuous variables were
compared between groups with Wilcoxon rank sum tests. Di-
chotomous variables were compared between groups by use
of χ2 and Fisher exact tests. Relationships between continuous
variables were assessed with Spearman’s rank order correlation
coefﬁcients. Adjusted differences between groups were assessed
with linear regression, with calculation of standard errors with
heteroskedasticity-consistent covariance matrix estimators and
log-transformation of outcomes when necessary to satisfy
model assumptions.
The rate and predictors of CD4+ T-cell count recovery
among UARTO participants achieving a plasma HIV RNA
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level of <400 copies/mL by month 6 of ART were assessed with
linear mixed models (PROC MIXED in SAS). A 3-piece seg-
mented linear model (0–3 months, 3–12 months, and >12
months) allowed for changing slopes of CD4+ T-cell count recov-
ery over time. Observations were censored at the time of a subse-
quent plasma HIV RNA level of >1000 copies/mL. Baseline
predictors of the rate of CD4+ T-cell count recovery in each seg-
ment were assessed with time-by-interaction terms. Factors asso-
ciated with the rate of CD4+ T-cell count recovery in unadjusted
analyses (P < .10) were included as potential confounders in mul-
tivariable models. Predictors of mortality were assessed with Ka-
plan-Meier methods and Cox proportional hazards models for
adjusted analyses.
RESULTS
Participant Characteristics Before ART Initiation
A total of 435 treatment-naive HIV-infected adults were includ-
ed in these analyses. Most (70%) were female, 23 of whom re-
ported being pregnant. At the time of ART initiation, the
median age was 34 years (interquartile range [IQR], 28–39
years), the median CD4+ T-cell count was 133 cells/mm3
(IQR, 79–201 cells/mm3), and the median plasma HIV RNA
level was 5.0 log10 copies/mL (IQR, 4.5–5.3 log10 copies/mL;
Table 1). As reported previously, the median pre-ART frequen-
cy of activated (CD38+HLA-DR+) CD8+ T cells was 67% (IQR,
57%–76%) [28]. Before ART, the median plasma KT ratio was
130 nM/µM (IQR, 90–200 nM/µM), and the median plasma
LPS level was 16 pg/mL (IQR, 12–24 pg/mL).
Correlates of the Pre-ART KT Ratio
In unadjusted analyses, a higher pre-ART KT ratio was associ-
ated with higher plasma HIV RNA levels (ρ = 0.38; P < .001),
lower CD4+ T-cell counts (ρ =−0.16; P < .001), higher plasma
LPS levels (ρ = 0.13; P = .007), and higher frequencies of
activated (CD38+HLA-DR+) CD4+ T cells (ρ = 0.32; P < .001)
and CD8+ T cells (ρ = 0.20; P < .001; Figure 1). Nonpreg-
nant women had a higher median pre-ART KT ratio than
men (141 vs 122 nM/µM; P = .047) and pregnant women
(115 nM/µM; P = .017). In a multivariable model including
each of these factors, a higher KT ratio was associated with high-
er plasma HIV RNA levels (P < .001), lower CD4+ T-cell counts
P = .005), higher LPS levels (P = .042), higher frequency of acti-
vated CD4+ T cells (P < .001), and female sex (P = .024). There
was no evidence for an association between age and pre-ART
KT ratio.
Impact of Suppressive ART on the Plasma KT Ratio
Among UARTO participants with a plasma HIV RNA level of
<400 copies/mL at month 6 of ART, the KT ratio decreased dur-
ing ART by a mean of 46% (median level at month 6, 72 nM/µM
[IQR, 56–94 nM/µM]; Figure 2A). Among those continuing to
maintain a plasma HIV RNA level of <400 copies/mL at month
12 of ART, the KT ratio continued to decline—albeit at a slower
rate—by a mean of 15% between months 6 and 12 (P < .001) to a
median of 62 nM/µM (IQR, 49–78 nM/µM). Despite ART-medi-
ated declines in the KT ratio, the pre-ART KT ratio continued to
be a strong predictor of the KT ratio at month 12 of ART-medi-
ated viral suppression (ρ = 0.56; P < .001; Figure 2B).
Relationship Between the Plasma KT Ratio and CD4+ T-Cell
Count Recovery
We next assessed the relationship between the pre-ART KT
ratio and subsequent CD4+ T-cell count recovery among
those achieving a plasma HIV RNA level of <400 copies/mL
by month 6 of ART (n = 408). Median follow-up during
ART-mediated viral suppression was 38 months (IQR, 22–47
months), and participants contributed a median of 12 CD4+
T-cell count observations (IQR, 7–15 observations) before cen-
soring. While there was no evidence for a relationship between
the pre-ART KT ratio and the rate of CD4+ T-cell count recov-
ery between months 0–3 and 3–12 of ART, each 2-fold increase
in the pre-ART KT ratio was associated with 1 fewer CD4+
T cell gained per month (95% conﬁdence interval [CI], −1.8
to −.01 cells/mm3 per month; P = .046) following month 12
of ART, after adjustment for pre-ART CD4+ T-cell count and
plasma HIV RNA level, age, and sex (each with time-interaction
terms). Since the pre-ART KT ratio was a strong predictor of
month 12 KT ratio, we next assessed the relationship between
the month 12 KT ratio and subsequent CD4+ T-cell count re-
covery among those with plasma HIV RNA levels of <400 cop-
ies/mL at month 12 of ART. In unadjusted analyses, a higher
month 12 KT ratio during conﬁrmed ART-mediated viral sup-
pression predicted a subsequent mean 1.3 fewer CD4+ T cells/
mm3 gained per month (95% CI, −2.2 to −.3 cells/mm3 per
month; P = .010; Table 2). Even after adjustment for pre-ART
plasma HIV RNA level, age, sex, and both month 12 CD4+
Table 1. Characteristics of Human Immunodeﬁciency Virus
(HIV)–infected Ugandans Initiating Antiretroviral Therapy
Characteristic Value
Age, years 34 (28–39)
Female sex 305 (70)
CD4+ T-cell count, cells/mm3 133 (79–201)
Plasma HIV RNA level, log10 copies/mL 5.0 (4.6–5.5)
BMIa 21 (19–24)
CD38+HLA-DR+ CD8+ T cells, % 67 (56–76)
Plasma tryptophan level, µM 18 (11–23)
Plasma kynurenine level, nM 2157 (1734–2709)
Plasma KT ratio, nM/µM 131 (92–198)
Data are no. (%) of patients or median (interquartile range).
Abbreviation: KT ratio, ratio of kynurenine to tryptophan.
a Body mass index (BMI) is defined as the weight in kilograms divided by the
height in meters squared.
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T-cell count and CD8+ T-cell activation, each 2-fold increase
in themonth 12 KT ratio continued to predict a subsequent mean
2 cells/mm3 fewer CD4+ T cells gained per month (95% CI, −3.1
to−.8 cells/mm3; P = .001). Results were similar when adding the
pre-ART CD4+ T-cell count and its time interaction term to the
model (mean of 2.2 fewer cells/mm3/month per 2-fold increase in
month 12 KT ratio; P < .001). These relationships were essentially
unchanged in sensitivity analyses excluding women who were
pregnant at month 12 (n = 9). It is also important to note that
the pre-ART and month 12 KT ratio are collinear (Figure 2B),
such that when both the pre-ART and month 12 KT ratios are
included in the same model, the effect of each measurement on
the slope of the CD4+ T-cell count recovery was rendered insig-
niﬁcant (data not shown). This may suggest that the impact of a
Figure 1. Factors associated with the plasma ratio of kynurenine to tryptophan (hereafter, the “KT ratio”) before antiretroviral therapy (ART) initiation in
human immunodeﬁciency virus (HIV)–infected Ugandans. The relationships between the pre-ART KT ratio and the CD4+ T-cell count (A), the plasma HIV
RNA level (B ), sex and pregnancy status (C ), CD4+ T-cell activation (D ), CD8+ T-cell activation (E ), and plasma lipopolysaccharide (LPS) level (LPS, F ) were
assessed in 435 HIV-infected Ugandans. Between-group comparisons were assessed with Wilcoxon rank sum tests, and Spearman correlation coefﬁcients
were used for comparing continuous variables.
Figure 2. Impact of antiretroviral therapy (ART)–mediated viral suppression on the plasma ratio of kynurenine to tryptophan (hereafter, the “KT ratio”) in
human immunodeﬁciency virus (HIV)–infected Ugandans. Changes in the KT ratio were assessed in HIV-infected Ugandans during the ﬁrst year of conﬁrmed
ART-mediated viral suppression to <400 copies/mL (A). Boxes represent interquartile ranges, and central bars reﬂect median values. Error bars span the 5th
and 95th percentile values. P values reﬂect changes from baseline levels assessed with linear mixed models. The correlation between the pre-ART KT ratio
and the month 12 KT ratio was also assessed (B ).
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persistently high KT ratio on the CD4+ T-cell count recovery dur-
ing ARTmay be largely determined by the extent of immune dys-
function before ART initiation.
Relationship Between the Plasma KT Ratio and Mortality
Thirty-nine participants died after initiating ART, with nearly half
of the deaths occurring within the ﬁrst 6 months of ART. As most
UARTO participants live in a rural resource-limited environment,
many of the deaths occurred at home, and the cause of death is
unknown for the majority of cases. Nonetheless, a higher pre-
ART KT ratio strongly predicted increased mortality during
ART (P for trend < .001; Figure 3A). Since a higher pre-ART
KT ratio might conceivably be a consequence of a subclinical ill-
ness that would subsequently cause death during early ART (eg,
Table 2. Predictors of Late CD4+ T-Cell Count Recovery Among Human Immunodeﬁciency Virus (HIV)–Infected Ugandans Receiving
Suppressive Antiretroviral Therapy
Characteristic
Unadjusted Adjusteda
Change in CD4+ T-Cell Count P Change in CD4+ T-Cell Count P
Per month of study +3.0 (2.5–3.4) <.001 +2.7 (1.7–3.6) <.001
Month 12 plasma KT ratio
Per 2-fold increase +47.9 (7.5–88.2) .02 +49.5 (11.0–87.8) .012
Per month of studyb −1.3 (−2.2 to −.3) .010 −2.0 (−3.1 to −0.8) .001
Month 12 CD4+ T-cell count
Per 100 cell/mm3 increase +72.4 (55.0–89.8) <.001 +65.8 (42.1–89.6) <.001
Per month of studyb −0.3 (−.7 to .03) .07 −0.4 (−.8 to −.01) .045
Month 12 CD8+ T-cell activation
Per 10 percentage-point increase −34.2 (−51.5 to −16.9) <.001 −14.9 (−30.9 to 1.1) .068
Per month of studyb +0.1 (−.4 to .5) .78 −0.01 (−.5 to .4) .96
Female sex
Overall +26.3 (−15.7 to 68.2) .22 +17.3 (−30.0 to 64.7) .47
Per month of studyb +1.1 (.1–2.1) .028 +0.9 (−.3 to 2.1) .15
Age
Per 10-year increase −19.8 (−43.2 to 3.5) .096 +3.2 (−2.4 to 3.0) .82
Per month of studyb −0.4 (−.9 to .2) .21 +0.1 (−.7 to .9) .90
Pretherapy plasma HIV RNA level
Per log10 copies/mL increase −30.6 (−56.1 to −5.1) .019 −23.5 (−46.1 to −.9) .041
Per month of studyb +0.1 (−.5 to .7) .75 +0.5 (−.2 to 1.1) .14
Data are mean no. of cells/mm3 (95% confidence interval).
a Adjusted models include all listed factors.
b This is a factor-by-time interaction term, which reflects the association between each unit increase in the primary factor on the rate of CD4+ T-cell recovery (in CD4+
T-cells/mm3 per month).
Figure 3. Relationship between the plasma ratio of kynurenine to tryptophan (hereafter, the “KT ratio”) and mortality among human immunodeﬁciency
virus (HIV)–infected Ugandans initiating antiretroviral therapy (ART). The relationship between the KT ratio measured before ART initiation (A) and at month
6 of ART-mediated viral suppression of <400 copies/mL (B) and subsequent mortality was assessed with Kaplan-Meier methods. The KT ratio at each time
point was assessed in tertiles, and P values reﬂect ﬁndings from tests for trend.
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via an immune reconstitution inﬂammatory syndrome [IRIS]), we
also assessed the prognostic signiﬁcance of the month 6 KT ratio
among those with plasma HIV RNA levels of <400 copies/mL
during ART (n = 348). Each tertile increase in the month 6 KT
ratio was also strongly predictive of subsequent mortality (P for
trend = .012), with the vast majority of deaths occurring at least
1 year after the measurement (Figure 3B). We next assessed
whether these relationships were independent of other known
clinical predictors of mortality. Lower pre-ART CD4+ T-cell
counts and body mass index, male sex, and higher plasma HIV
RNA levels were all associated with increased mortality in unad-
justed models (Table 3). Even after adjustment for these factors
and age, each 2-fold increase in the pre-ART plasma KT ratio
was associated with a 1.8-fold increased risk of mortality
(P = .016). As we have previously reported [28], in addition to
the factors described above, the extent of CD8+ T-cell activation
at month 6 of suppressive ART was also predictive of subsequent
mortality in unadjusted models. Even after adjustment for age, sex,
pre-ART CD4+ T-cell count, pre-ART plasma HIV RNA level,
and extent of CD8+ T-cell activation at month 6 of suppressive
ART, each 2-fold increase in the month 6 KT ratio was associated
with a 3.7-fold increased risk of subsequent mortality (P = .008).
These relationships were essentially unchanged in sensitivity anal-
yses excluding women who were pregnant at baseline (n = 24) or
month 6 (n = 6). While a minority of deaths (16 of 39) had avail-
able dietary diversity data, we found no evidence that the number
of self-reported dietary protein sources modiﬁed the association
between the KT ratio and mortality (P for interaction = .66).
DISCUSSION
While the kynurenine pathway of tryptophan catabolism—
induced either by host IDO activity or possibly upon enrich-
ment of gut-resident bacteria with IDO-like enzymes—has
been associated with microbial translocation, systemic immune
activation, and proliferative T-cell defects during HIV infection
[10, 13, 20], no prior study had assessed the relationship be-
tween this pathway and clinical outcomes during treated HIV
disease. In our current study, we evaluated the prognostic signif-
icance of the plasma KT ratio—a marker of systemic induction
of IDO and IDO-like enzymes—in a cohort of 435 HIV-
infected Ugandans starting their ﬁrst ART regimen. We found
that a higher pre-ART KT ratio (which reﬂects greater metabo-
lism of tryptophan to its metabolites) was strongly associated
with higher plasma HIV RNA levels, lower CD4+ T-cell counts,
and female sex and was modestly associated with higher plasma
LPS levels. Furthermore, a higher plasma KT ratio—both before
ART and during ART-mediated viral suppression—strongly and
independently predicted lower late CD4+ T-cell count recovery
and increased mortality. While it remains unclear whether the
kynurenine pathway is causally associated with CD4+ T-cell
count recovery and mortality, these data provide the ﬁrst evi-
dence supporting the potential clinical relevance of IDO activity
and the kynurenine pathway in treated HIV disease.
Consistent with earlier studies in resource-rich settings [13,
21, 22], we observed strong relationships between the extent of
HIV replication and CD4+ T-cell depletion in plasma KT ratio
Table 3. Predictors of Mortality Among Human Immunodeﬁciency Virus (HIV)–Infected Ugandans Initiating Antiretroviral Therapy (ART)
Characteristic
Unadjusted Adjusteda
HR (95% CI) P HR (95% CI) P
Pre-ART Factors?
Pre-ART KT ratio, per 2-fold increase 2.0 (1.4–3.0) <.001 1.80 (1.1–2.9) .016
Pre-ART CD4+ T-cell count, per 100 cells/mm3 increase 0.58 (.38–.87) .008 0.63 (.38–1.1) .08
BMI, per kg/m2 increase 0.78 (.70–.88) <.001 0.79 (.68–.91) .001
Female sex 0.53 (.28–.99) .049 1.1 (.48–2.5) .83
Pre-ART plasma HIV RNA level, per log10 copies/mL increase 1.75 (1.1–2.9) .026 1.1 (.57–2.1) .79
Age, per 10-year increase 1.3 (.92–1.8) .13 1.3 (.82–2.0) .28
After month 6 of ART for those with an HIV RNA load <400 copies/mL
Month 6 KT ratio, per 2-fold increase 2.8 (1.3–5.8) .006 3.7 (1.4–9.7) .008
Pre-ART CD4+ T-cell count, per 100 cells/mm3 increase 0.71 (.38–1.3) .29 0.52 (.22–1.2) .14
BMI, per kg/m2 increase 0.84 (.70–1.0) .053 0.83 (.65–1.1) .14
Female sex 0.38 (.13–1.08) .069 0.49 (.11–2.1) .34
Pre-ART plasma HIV RNA level, per log10 copies/mL increase 1.7 (.75–4.1) .20 1.0 (.24–4.1) .99
Age, per 10-year increase 1.8 (.92–3.4) .091 1.5 (.70–3.2) .30
Month 6 percentage of activated CD8+ T cells, per 2-fold increase 4.3 (1.01–18.7) .049 4.1 (.68–25) .12
Abbreviations: BMI, body mass index; CI, confidence interval; KT ratio, ratio of kynurenine to tryptophan; OR, odds ratio.
a Adjusted models include all listed factors.
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and the untreated HIV-infected Ugandans with advanced AIDS
in our study. Like our group’s recent study in San Francisco, we
also observed a modest relationship between the plasma KT
ratio and LPS levels, conﬁrming a link between the kynurenine
pathway and microbial translocation in an African cohort [13].
Interestingly, we also observed higher plasma KT ratio levels in
women than men after adjustment for differences in plasma
HIV RNA levels. This is consistent with prior studies suggesting
that women have more-robust innate immune responses to
Toll-like receptor 7 stimulation by HIV than men [32]. Future
studies evaluating the inﬂuence of sex hormones on IDO induc-
tion, as well as the longitudinal impact of pregnancy on the KT
ratio, would also be of signiﬁcant interest. Like earlier studies
from resource-rich settings [22], we also conﬁrmed in a rural
African setting that ART-mediated viral suppression results in
a robust decline in the plasma KT ratio. Nevertheless, in our
Ugandan study, the KT ratio appeared to plateau by month
12 of suppressive ART at levels that are still well above those
observed in our cohort of patients in San Francisco with ART-
suppressed HIV levels (median, 62 nM/µM vs 37 nM/µM)
and in a cohort of North American patients with ART-
suppressed HIV levels who had a history of advanced AIDS
in the Study of the Ocular Complications of AIDS (median,
50 nM/µM), all assessed in the same laboratory [13, 33].
These levels are also >2-fold higher than reported in other
studies of European healthy blood donors or HIV-uninfected
control populations (median, 25–28 nM/uM) [22,34]. While we
did not have a matched HIV-uninfected Ugandan control group
to determine whether these levels were abnormally high for this
setting, and while there are clearly many potential differences be-
tween cohorts that could explain differences, these levels did ap-
pear to persist at high levels in treated HIV-infected Ugandans.
We also demonstrated that both the pretherapy and month
12 KT ratio strongly and independently predicted late (ie,
after 12 months) CD4+ T-cell count recovery. While the impact
of the month 12 KT ratio on the adjusted rate of CD4+ T-cell
count recovery might seem of modest clinical signiﬁcance
(−2 cells/mm3/month per 2-fold increase), this translates into
an absolute difference of −240 cells/mm3 over 10 years and
−480 cells/mm3 over 20 years of suppressive ART, which
could potentially be clinically signiﬁcant for individuals starting
ART at low CD4+ T-cell counts. Importantly this effect was
stronger than and independent of the relationship we previously
reported between pretherapy CD8+ T-cell activation and CD4+
T-cell count recovery from this same cohort [28], potentially
suggesting that the kynurenine pathway is more closely linked
to the biologic pathways mediating CD4+ T-cell count recovery
than the extent of T-cell activation. The fact that kynurenine
and other downstream catabolites suppress T-cell proliferation
in vitro may be one mechanism to explain these ﬁndings [9, 10].
Alternatively, reduction in Th17 cell levels in mucosal tissues by
the catabolite 3-HAA may lead to decreased tight junctions
between gut epithelial cells and decreased bacterial clearance,
leading to microbial translocation, which could suppress
T-cell proliferation through alternative mechanisms [35]. It is
also notable that the pre-ART KT ratio did not predict early
(ie, during the ﬁrst 3 months) ART-mediated CD4+ T-cell
count recovery. This may be because those with higher pre-
ART KT ratios experience greater declines (on an absolute
scale) in the KT ratio (and potentially a greater reversal of pro-
liferative defects) and/or greater declines in plasma HIV RNA
levels, resulting in greater redistribution of CD4+ T cells from
lymphoid tissues [36].
Even more importantly, we established that plasma KT ratio
measured both before ART and at month 6 of suppressive ART
strongly and independently predict increased mortality. While
many of the deaths occurred in the ﬁrst few months of ART
and may have represented IRIS events against subclinical infec-
tions that were contributing to higher pre-ART KT ratio levels,
KT ratio levels measured after 6 months of conﬁrmed suppres-
sive ART continued to predict subsequent mortality, with the
majority of deaths occurring over a year after the measurement,
making it less likely that the higher KT ratio was simply a con-
sequence of a prefatal illness. This relationship was also notably
stronger than and independent of CD8+ T-cell activation, which
we had previously reported to predict mortality in this same co-
hort [28], again suggesting that the kynurenine pathway is more
closely linked to the mechanistic pathways mediating the risk of
mortality than to T-cell activation.
Since this was an observational study, it remains unclear
whether the kynurenine pathway is causally associated with
clinical outcomes or simply a marker of some other related im-
munologic process (ie, innate immune activation) that causes
poor CD4+ T-cell count recovery and mortality through inde-
pendent mechanisms. Given the many potentially bidirectional
relationships between the kynurenine pathway, microbial trans-
location, and innate immune activation, future mediation and/
or pathway studies with additional immunologic markers will
be necessary to further address this question, as will clinical tri-
als of targeted interventions. Indeed, several IDO inhibitors are
in clinical development for treatment of cancer [37, 38]. Last, it
should be noted that all the participants in our study came from
southwestern Uganda and that all had advanced HIV disease at
the time of ART initiation. Future studies in other settings and
with less advanced populations will be necessary before these
observations can be generalized to other populations of HIV-in-
fected individuals.
In summary, our study is the ﬁrst to demonstrate that kynur-
enine pathway activity predicts poor CD4+ T-cell count recov-
ery and increased mortality during treated HIV disease. These
data provide the ﬁrst evidence that the kynurenine pathway may
be clinically relevant in treated HIV disease. Whether this path-
way is causally associated with disease will need to be assessed in
future mechanistic studies, but these data highlight IDO and the
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kynurenine pathway more generally as a potential target for fu-
ture interventional studies.
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